Smith Integrative Oncology warns about black market Retatrutide and patient safety risks.

{
  "signal_id": "4736db19-b798-40b9-bace-5d5278648de1",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-08-13T07:47:37.443+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "tags": [
      "Pharmaceuticals",
      "Compliance",
      "Healthcare Technology"
    ],
    "summary": "Smith Integrative Oncology warns about black market Retatrutide and patient safety risks.",
    "post_url": "https://www.linkedin.com/posts/eli-lilly-and-company_real-medicine-activity-7493296413167206400-jCqi",
    "num_likes": 283,
    "post_text": "Obesity management medicines are all over the headlines - and some bad actors are exploiting that attention on the black market.\n\nRetatrutide is an investigational molecule still in clinical trials and is not approved for sale to consumers anywhere in the world. Any product marketed as retatrutide or “reta” poses serious potential risks to patient health.\n\nPatient safety matters. Learn more: https://lnkd.in/eutEiPNt",
    "initiatives": [
      {
        "topic": "patient education on drug safety",
        "urgency": 0.6
      }
    ],
    "pain_points": [
      {
        "topic": "black market sales of investigational drugs",
        "intensity": 0.8
      },
      {
        "topic": "patient safety risks from unapproved medications",
        "intensity": 0.75
      }
    ],
    "posted_date": "2026-08-12T13:24:43.614Z",
    "num_comments": 5,
    "technologies_mentioned": [
      {
        "name": "Retatrutide",
        "status": "evaluating"
      }
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/4736db19-b798-40b9-bace-5d5278648de1 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'